AVIR

Atea Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↓ 1/10
  • Value↓ 4/10
Atea Pharmaceuticals sales and earnings growth
AVIR Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -27.88%
  • FCF Y/Y↓ -17.17%
Atea Pharmaceuticals gross and profit margin trends
AVIR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -45.83%
Atea Pharmaceuticals net debt vs free cash flow
AVIR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Atea Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks